一个临床预测模型,用于早期大肠切除术的患者,严重的性结肠炎治疗的tacrolimus
Hikaru Shimizu1, Kazuki Kakimoto1, Mai Utsumi1
12nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
JGH open : an open access journal of gastroenterology and hepatology
|October 27, 2025
概括
一个新的模型预测了用tacrolimus治疗的性结肠炎患者的切口风险. 早期识别高风险个体有助于手术时间和治疗决策.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 塔克罗利斯有效治疗耐火性性结肠炎 (UC).
- 一些患者尽管接受了塔克罗利斯治疗,但仍需要进行大肠切除术.
- 早期的手术风险评估对于最佳的患者结果至关重要.
研究的目的:
- 在开始服用塔克罗利斯后3个月内识别胆管切除术的预测因素.
- 开发一种临床上适用的预测模型,用于早期切除术风险.
主要方法:
- 对114名住院治疗tacrolimus (2011-2025) 的严重UC患者进行了回顾性分析.
- 经过 LASSO 处罚的逻辑回归与交叉验证以确定预测变量.
- 模型开发使用血清白蛋白,血红蛋白和塔克罗利开始时的年龄.
主要成果:
- 21.1%的患者接受了小肠切除术;14.0%在3个月内.
- 预测模型显示出良好的歧视 (AUC 0.78).
- 通过模型识别的高风险群体具有显著更高的累积切除术率 (p < 0.001).
结论:
- 临床预测模型根据基线因素准确估计了早期切除术风险.
- 该模型可以指导手术时间和治疗策略决策.
- 这种工具有助于管理耐火性性结肠炎患者.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Inflammatory Bowel Disease V: Surgical Management
438
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
438
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Inflammatory Bowel Disease I: Ulcerative Colitis
882
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
882
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480


